Title:
METHODS OF TREATING CANCER USING CYPLASTIN COMBINED WITH A DIOXOLANE NUCLEOSIDE SUCH AS TROXACITABINE
Document Type and Number:
WIPO Patent Application WO2002078678
Kind Code:
A3
Abstract:
The present invention provides a novel method for treating a patient with cancer comprising administering to the patient a therapeutically effective amount of cisplatin and a compound having the formula (I), wherein B is cytosine or 5-fluorocytosine and R is selected from the group comprising H, monophosphate, diphosphate, triphosphate, carbonyl substituted with a C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C6-10 aryl, and (II) wherein each Rc is independently selected from the group comprising H, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and a hydroxy protecting group.
Inventors:
JOLIVET JACQUES (CA)
Application Number:
PCT/CA2002/000439
Publication Date:
March 27, 2003
Filing Date:
March 28, 2002
Export Citation:
Assignee:
SHIRE BIOCHEM INC (CA)
JOLIVET JACQUES (CA)
JOLIVET JACQUES (CA)
International Classes:
A61K31/513; A61K33/243; A61K45/06; A61P35/00; (IPC1-7): A61K31/506; A61P35/00
Domestic Patent References:
| WO1996007413A1 | 1996-03-14 | |||
| WO2000057861A2 | 2000-10-05 |
Other References:
PATNAIK A ET AL: "A phase I and pharmacokinetic (PK) study of the L-nucleoside analog, troxacitabine (BCH-4556) with cisplatin;cisplatin-associated reduction of troxacitabine clearance.", PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL, no. 41, March 2000 (2000-03-01), 91st Annual Meeting of the American Association for Cancer Research.;San Francisco, California, USA; April 01-05, 2000, March, 2000, pages 815 - 816, XP001098899, ISSN: 0197-016X
KADHIM S A ET AL: "POTENT ANTITUMOR ACTIVITY OF A NOVEL NUCLEOSIDE ANALOGUE, BCH-4556 (BETA-L-DIOXOLANE-CYTIDINE), IN HUMAN RENAL CELL CARCINOMA XENOGRAFT TUMOR MODELS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 21, 1 November 1997 (1997-11-01), pages 4803 - 4810, XP000971188, ISSN: 0008-5472
WEITMAN S ET AL: "The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES APR 2000, vol. 6, no. 4, April 2000 (2000-04-01), pages 1574 - 1578, XP001098898, ISSN: 1078-0432
HARDMAN W E ET AL: "EFFICACY OF TREATMENT OF COLON, LUNG AND BREAST HUMAN CARCINOMA XENOGRAFT WITH: DOXORUBICIN, CISPLATIN, IRINOTECAN OR TOPOTECAN", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 19, 1999, pages 2269 - 2274, XP008006680, ISSN: 0250-7005
MERK RESEARCH LABORATORIES: "The Merk Index", 2001, MERK & CO, NJ, USA, XP002220297
KADHIM S A ET AL: "POTENT ANTITUMOR ACTIVITY OF A NOVEL NUCLEOSIDE ANALOGUE, BCH-4556 (BETA-L-DIOXOLANE-CYTIDINE), IN HUMAN RENAL CELL CARCINOMA XENOGRAFT TUMOR MODELS", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 57, no. 21, 1 November 1997 (1997-11-01), pages 4803 - 4810, XP000971188, ISSN: 0008-5472
WEITMAN S ET AL: "The new dioxolane, (-)-2'-deoxy-3'-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts.", CLINICAL CANCER RESEARCH: AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH. UNITED STATES APR 2000, vol. 6, no. 4, April 2000 (2000-04-01), pages 1574 - 1578, XP001098898, ISSN: 1078-0432
HARDMAN W E ET AL: "EFFICACY OF TREATMENT OF COLON, LUNG AND BREAST HUMAN CARCINOMA XENOGRAFT WITH: DOXORUBICIN, CISPLATIN, IRINOTECAN OR TOPOTECAN", ANTICANCER RESEARCH, HELENIC ANTICANCER INSTITUTE, ATHENS,, GR, vol. 19, 1999, pages 2269 - 2274, XP008006680, ISSN: 0250-7005
MERK RESEARCH LABORATORIES: "The Merk Index", 2001, MERK & CO, NJ, USA, XP002220297
Download PDF: